104 related articles for article (PubMed ID: 16241976)
1. Clinical and immune responses correlate in glatiramer acetate therapy of multiple sclerosis.
Weder C; Baltariu GM; Wyler KA; Gober HJ; Lienert C; Schluep M; Radü EW; De Libero G; Kappos L; Duda PW
Eur J Neurol; 2005 Nov; 12(11):869-78. PubMed ID: 16241976
[TBL] [Abstract][Full Text] [Related]
2. Glatiramer acetate-specific antibody titres in patients with relapsing / remitting multiple sclerosis and in experimental autoimmune encephalomyelitis.
Bomprezzi R; Schaefer R; Reese V; Misra A; Vollmer TL; Kala M
Scand J Immunol; 2011 Sep; 74(3):219-226. PubMed ID: 21615449
[TBL] [Abstract][Full Text] [Related]
3. Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate.
Tumani H; Kassubek J; Hijazi M; Lehmensiek V; Unrath A; Süssmuth S; Lauda F; Kapfer T; Fang L; Senel M; Brettschneider J
Eur Neurol; 2011; 65(3):164-9. PubMed ID: 21372576
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients.
Río J; Rovira A; Tintoré M; Sastre-Garriga J; Castilló J; Auger C; Nos C; Comabella M; Tur C; Vidal Á; Montalbán X
Mult Scler; 2014 Oct; 20(12):1602-8. PubMed ID: 24622350
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.
Carrieri PB; Carbone F; Perna F; Bruzzese D; La Rocca C; Galgani M; Montella S; Petracca M; Florio C; Maniscalco GT; Spitaleri DL; Iuliano G; Tedeschi G; Della Corte M; Bonavita S; Matarese G
Metabolism; 2015 Sep; 64(9):1112-21. PubMed ID: 25986733
[TBL] [Abstract][Full Text] [Related]
6. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis.
Valenzuela RM; Costello K; Chen M; Said A; Johnson KP; Dhib-Jalbut S
Mult Scler; 2007 Jul; 13(6):754-62. PubMed ID: 17613604
[TBL] [Abstract][Full Text] [Related]
7. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G; Filippi M; Wolinsky JS
Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
[TBL] [Abstract][Full Text] [Related]
8. Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis.
Dhib-Jalbut S; Chen M; Henschel K; Ford D; Costello K; Panitch H
Mult Scler; 2002 Dec; 8(6):485-91. PubMed ID: 12474988
[TBL] [Abstract][Full Text] [Related]
9. Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis. A pilot study.
Farina C; Wagenpfeil S; Hohlfeld R
J Neurol; 2002 Nov; 249(11):1587-92. PubMed ID: 12420101
[TBL] [Abstract][Full Text] [Related]
10. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis.
Khan O; Shen Y; Caon C; Bao F; Ching W; Reznar M; Buccheister A; Hu J; Latif Z; Tselis A; Lisak R
Mult Scler; 2005 Dec; 11(6):646-51. PubMed ID: 16320723
[TBL] [Abstract][Full Text] [Related]
11. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
De Stefano N; Filippi M; Hawkins C;
J Neurol Sci; 2008 Mar; 266(1-2):44-50. PubMed ID: 17897678
[TBL] [Abstract][Full Text] [Related]
12. Failure of glatiramer acetate to modify the peripheral T cell repertoire of relapsing-remitting multiple sclerosis patients.
Berthelot L; Miqueu P; Pettré S; Guillet M; Moynard J; Wiertlewski S; Lefrère F; Brouard S; Soulillou JP; Laplaud DA
Clin Immunol; 2010 Apr; 135(1):33-42. PubMed ID: 20116333
[TBL] [Abstract][Full Text] [Related]
13. [Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis].
Oreja-Guevara C; Bermejo PE; Miralles A; Gabaldón L; Aguilar MJ; Díez-Tejedor E
Neurologia; 2009 Sep; 24(7):435-8. PubMed ID: 19921551
[TBL] [Abstract][Full Text] [Related]
14. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M;
Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268
[TBL] [Abstract][Full Text] [Related]
15. Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis.
Caon C; Din M; Ching W; Tselis A; Lisak R; Khan O
Eur J Neurol; 2006 May; 13(5):471-4. PubMed ID: 16722971
[TBL] [Abstract][Full Text] [Related]
16. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.
Ziemssen T; Kümpfel T; Klinkert WE; Neuhaus O; Hohlfeld R
Brain; 2002 Nov; 125(Pt 11):2381-91. PubMed ID: 12390966
[TBL] [Abstract][Full Text] [Related]
17. Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.
Dressel A; Vogelgesang A; Brinkmeier H; Mäder M; Weber F
J Neuroimmunol; 2006 Dec; 181(1-2):133-40. PubMed ID: 17084909
[TBL] [Abstract][Full Text] [Related]
18. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
[TBL] [Abstract][Full Text] [Related]
19. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
20. Glatiramer acetate treatment of multiple sclerosis: an immunological perspective.
Racke MK; Lovett-Racke AE
J Immunol; 2011 Feb; 186(4):1887-90. PubMed ID: 21289312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]